Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: Possible upregulation by Epstein-Barr virus latent membrane protein 1

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 265-272

  Siegler, Gabriele ^a   Meyer, Birgit ^a   Dawson, Chris ^b   Brachtel, Elena ^c   Lennerz, Jochen ^a   Koch, Claudia ^a   Kremmer, Elisabeth ^d   Niedobitek, Edith ^e   Gonnella, Roberta ^f   Pilch, Ben Z ^c   Young, Lawrence S ^b   Niedobitek, Gerald ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epstein Barr virus; LMP1; Nasopharyngeal carcinoma; TRAF1

Indexed keywords

LATENT MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; VIRUS INFECTION;

ANTIGENS, VIRAL; APOPTOSIS; CAPSID; CARCINOMA; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NASOPHARYNGEAL NEOPLASMS; PROTEIN BIOSYNTHESIS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 1; TUMOR CELLS, CULTURED; UP-REGULATION; VIRAL MATRIX PROTEINS;

EID: 4544293608     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20367     Document Type: Article

References (37)

1. Niedobitek G, Meru N, Delecluse H-J. Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 2001;82:149-70.
2. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
3. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963-8.
4. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
5. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor-κB. J Biol Chem 1992;267:24157-60.
6. Fries KL, Miller WE, Raab-Traub N. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology 1999;264:159-66.
7. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS, Raab-Traub N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activating regions 1 and 2. J Virol 1999;73:5548-55.
8. Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res 2002;62:6337-44.
9. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001;98:6905-10.
10. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
11. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998;17:1700-9.
12. Floettmann JE, Eliopoulos AG, Jones M, Young LS, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) signaling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene 1998;17:2383-92.
13. Rowe M. The EBV latent membrane protein-1 (LMP1): a tale of two functions. EBV Rep 1995;2:99-104.
14. Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E, Mosialos G. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κ B through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ. Proc Natl Acad Sci USA 1998;95:10106-11.
15. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnem MF, Kieff E, Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 1996;16: 7098-108.
16. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
17. Eliopoulos AG, Gallagher NJ, Blake SMS, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274: 16085-96.
18. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-jun N-terminal kinase cascade. EMBO J 1997;16: 6478-85.
19. Eliopoulos A, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998;16:1731-42.
20. Eliopoulos AG, Waites ER, Blake SMS, Davies C, Murray P, Young LS. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. J Virol 2003;77:1316-28.
21. Vicat J-M, Ardila-Osorio H, Khabir A, Brezak M-C, Viossat I, Kasprzyk P, Jlidi R, Opolon P, Ooka T, Prevost G, Huang DP, Busson P. Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor. Biochem Pharmacol 2003;65:423-33.
22. Busson P, Ganem G, Flores P, Mugneret F, Clausse B, Caillou B, Braham K, Wakasugi H, Lipinski M, Tursz T. Establishment and characterisation of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988;42:599-606.
23. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-97.
24. Beck A, Päzolt D, Grabenbauer GG, Nicholls JM, Herbst H, Young LS, Niedobitek G. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma and Hodgkin's disease. J Pathol 2001;194:145-51.
25. Siegler G, Kremmer E, Gonnella R, Niedobitek G. Epstein-Barr virus-encoded latent membrane protein (LMP) 1 and TNF receptor-associated factors (TRAF): co-localisation of LMP1 and TRAF1 in EBV-associated lymphoproliferations in vivo. J Clin Pathol Mol Pathol 2003;56:156-61.
26. Niedobitek G, Herbst H. In situ detection of Epstein-Barr virus DNA and of viral gene products. In: Wilson JB, May GHW, eds. Epstein-Barr virus protocols. Totowa, NJ: Humana, 2001. 79-91.
27. Grässer FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994;84: 3792-8.
28. Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998;72:7900-8.
29. Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne RD, Shabaik A, Reed JC. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000;165:5084-96.
30. Ardila-Osorio H, Clausse B, Mishal Z, Wiels J, Tursz T, Busson P. Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer 1999;81:645-9.
31. Craxton A, Shu G, Graves JD, Sklatvala J, Krebs EG, Clark EA. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol 1998;161:3225-36.
32. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995;147:1152-60.
33. Zapata JM, Reed JC. TRAF1: Llord without a RING. Sci STKE 2002;133:PE27.
34. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, Geha RS. TRAF1 is a negative regulator of TNF signaling: enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001; 15:647-57.
35. Irmler M, Steiner V, Ruegg C, Wajant H, Tschopp J. Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Lett 2000;468:129-33.
36. Leo E, Devereaux QL, Buchholtz C, Welsh K, Matsuzawa S, Stennicke HR, Salvesen GS, Reed JC. TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis. J Biol Chem 2001;276:8087-93.
37. Jang HD, Chung YM, Baik JH, Choi YG, Park I-S, Jung YK, Lee SY. Caspase-cleaved TRAF1 negatively regulates the antiapoptotic signals of TRAF2 during TNF-induced cell death. Biochem Biophys Res Commun 2001;281:499-505.